Zitzmann K, Ruden JV, Brand S et al (2010) Compensatory activation of Akt in response to mTOR and Raf inhibitors—a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 295(1):100–109PubMedCrossRef

Carracedo A, Ma L, Teruya-feldstein J et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Investig 118(9):3065–3074PubMedCentralPubMed

Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50):7455–7464PubMedCrossRef

Parsons DW, Wang TL, Samuels Y et al (2005) Colorectal cancer: mutations in signaling pathway. Nature 436(7052):792PubMedCrossRef

Staal SP (1987) Molecular cloning of akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci 84:5034–5037PubMedCentralPubMedCrossRef

Brugge J, Hung MC, Mills GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer Cell 12(2):104–107PubMedCrossRef

Bleeker FE, Felicioni L, Buttitta F et al (2008) AKT1(E17K) in human solid tumors. Oncogene 27(42):5648–5650PubMedCrossRef

Ghayouri M, Boulware D, Nasir A et al (2010) Activation of the serine/threonine protein kinase Akt in enteropancreatic neuroendocrine tumors. Anticancer Res 30(12):5063–5067PubMed

Zitzmann K, Vlotides G, Brand S et al (2012) Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Endocr Relat Cancer 19(3):423–434PubMedCrossRef

Lin J, Sampath D, Nannini MA et al (2013) Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor model. Clin Cancer Res 19(7):1–13CrossRef

Gloesenkamp CR, Nitzsche B, Ocker M et al (2012) AKT inhibition by tricribine alone or as combination therapy for growth control in gastroenteropancreatic neuroendocrine tumors. Int J Oncol 40(3):876–888PubMed

Somnay Y, Simon K, Harrison AD et al (2013) Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro. Anti-cancer Drugs 24(1):66–72PubMedCentralPubMed

Yap TA, Yan L, Patnaik A et al (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29(35):4688–4695PubMedCrossRef

Hardt M, Chantaravisoot N, Tamanoi F et al (2011) Activating mutations of TOR (target of rapamycin). Genes Cells 16(2):141–151PubMedCentralPubMedCrossRef

Sato T, Nakashima A, Guo L et al (2010) Single aminoacid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29(18):2746–2752PubMedCentralPubMedCrossRef

Righi L, Volante M, Rapa I et al (2010) Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 17:977–987PubMedCrossRef

Zhou CF, Ji J, Yuan F et al (2011) mTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases. Hepatogastroenterology 58(112):1–11PubMed

Kasajima A, Pavel M, Darb-Esfahani S et al (2011) mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 18:181–192PubMedCrossRef